## HCV TREATMENT REFERRAL: END OF TREATMENT EVALUATION

**CDCR 7413-4 (Rev. 03/14)** Form: Page 1 of 1

Patient Information (to be com	pleted by referring clinician)
BASELINE INFORMATION:	MOST RECENT TREATMENT COURSE (continued):
Age EPRD Date of 1st Positive HCV test:	Was dose reduction necessary? ☐ no ☐ yes
Genotype/date	ii yes, iist which medication and why.
Genotype/date Date: Date: Date:	Were there interruptions in treatment? ☐ no ☐ yes
FIB4: Date: \( \sum \text{N/A} \)	If yes, describe:
History of cirrhosis □ no□yes if yes, Child-Pugh/date:	Did patient have any hospitalizations during treatment course?
Allergies □no□yes if yes, list:	☐ no ☐ yes If yes, list diagnosis and length of stay:
Prior to this treatment course, was patient treatment ☐ naïve ☐ experient fexperienced: ☐ null responder ☐ partial responder ☐ relapser;	
describe:	Were colony stimulating agents (epo, GCSF) required?  □ no □ yes If yes, list which medication and dates. Include
	Hgb and response if epo used and/or WBC/ANC and response if GCSF used:
MOST RECENT TREATMENT COURSE:	
(please attach completed HCV treatment flowsheet)	Any other complications associated with HCV treatment?  □ no □ yes If yes, please list:
Weeks indicated weeks completed Combination	□110 □ yes II yes, piease iist.
Did patient complete treatment?  yes  no If no, indicate why:	<del>_</del>
	Was CCHCS HCV warmline or outside hepatologist consulted in
Viral load response	regard to this patient's HCV treatment course? ☐ no ☐ yes
	If yes, specify which consultant and dates:
baseline 4 wk 8 wk □ N/A 12 wk 24 wk 48 wk □ N/A	
Referring Clinician Name and Title (Print):	
Referring Clinician Signature:	Date:
To be completed by CCHCS	HCV Oversight Committee
Date HCV treatment started Weeks of HCV treatment comple	ted
Regimen selected $\square$ pegylated interferon; $\square$ ribavirin; $\square$ boceprevir; $\square$	simeprevir;  □sofosbuvir;  □telaprevir
Assessment and Recommendations  1. HCV Successfully treated? ☐ yes ☐ no If no, describe:	
a. If successful completion of treatment course, primary care provide	er or HCV treating clinician to obtain viral load 12 weeks post-treatment
completion to ensure SVR.	
b. Refer back to primary care for further monitoring, including HCV s	creening, if appropriate, and education regarding risk reduction
strategies.	3, 11 1 , 3
-	
c. If treatment is not successful, may refer back for retreatment pend	ing the availability of new agents for the treatment of HCV.
Clinician Name and Title (Print):	Date:
Clinician Signature:	
	CDCR #:
L	ast Name:
<sub> </sub>	
	irst Name: MI:
	irst Name: MI:  OOB: